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Abstract 
The purpose of present work is to introduce the binding of existing drugs to the trans-disciplinary 
protein with the help of docking procedures. Docking procedures allows virtually screening a 
database of compounds and predict the strongest binder based on various scoring functions. This 
work has been performed with the help of Molegro Virtual docker, in which two drugs are docked 
with their corresponding and non-corresponding (trans-disciplinary) protein. Results reveals that the 
protein-ligand interaction energy, hydrogen bond energy and  MolDock scores provided by molegro 
virtual docker, between legands (Levodopa and Acyclovir) and trans-disciplinary proteins have 
been equivalent or even better than that of between legands and corresponding proteins. 
Key words: Docking; Protein-ligand interaction energy; hydrogen bond energy; Phenylalanine 
Hydroxylase; Deoxycytidine kinase 
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Introduction 
Docking procedures permits virtually screening a database of compounds and predict the strongest 
binder on various scoring functions. It finds ways in which two molecules, such as drugs and an 
enzyme and/or protein fit together and dock to each other well 
[1]
. 
Molecularly, docking techniques have been used in modern drug designing to understand drug–
receptor interaction. It has been stated in the literature that computational procedures strongly 
support more potent drugs by revealing the mechanism of drug-receptor interaction
[2]
.  
Rational Drug Design helps to facilitate and fasten the drug designing process, which involves 
various methods to identify novel compound, out of them one method is the docking of molecule of 
drug with the receptor
[3]
. 
Till date docking procedures have been used with legand to their corresponding proteins, but in this 
work it is being used with legands to trans-disciplinary proteins. Here trans-disciplinary reveals just 
the recognized proteins of another legand.  
Here two legands have been taken for carrying out this work, which are Levodopa and Acyclovir. 
Levodopa (CID no. 6047) has been recognized for anti-parkinsonism drug, whereas Acyclovir 
(CID no. 2022) as anti-herpes drug. Human Phenylalanine Hydroxylase (PDB ID 6PAH) is a 
recognized protein for Levodopa which catalyzes the hydroxylation of phenylalanine to tyrosine, 
which is a rate limiting step in catabolism of phenylalanine 
[4]
. Deoxycytidine kinase (dCK) (PDB 
ID 3MJR) is a recognized protein for Acyclovir which includes different deoxyribonucleoside 
kinases including the cytoplasmic (TK1) and mitochondrial (TK2) thymidine kinases. The dCK 
enzyme is associated with drug resistance and sensitivity, as both dCK and TK2 phosphorylate 
several antiviral and chemotherapeutic nucleoside analogs. For trans-disciplinary binding, 
Levodopa has been docked with Deoxycytidine kinase and Acyclovir with Phenylalanine 
Hydroxylase. 
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Materials  
For carrying out this work, National Center for Biotechnology Information’s (NCBI) website and 
Protein Data Bank’s (PDB) website were used as chemical and protein data sources. 
For docking studies, Molegro Virtual docker
[5]
 have been used.
 
Method 
Levodopa (CID no. 6047) and acyclovir (CID no. 2022) structure data files were downloaded from 
N.C.B.I. website and protein targets were downloaded from Protein Data Bank with PDB ID 6PAH 
and 3MJR respectively. 
Step 1-Docking of Legand (CID no. 6047) with corresponding target (PDB ID. 6PAH) 
Step 2-Docking of Legand (CID no. 2022) with corresponding target (PDB ID. 3MJR) 
Step 3-Docking of Legand (CID no. 6047) with trans-disciplinary target (PDB ID. 3MJR) 
Step 4-Docking of Legand (CID no. 2022) with trans-disciplinary target (PDB ID. 6PAH) 
Step 5-Comparing docking results of step 1 with docking results of step 3 
Step 6-Comparing docking results of step 2 with docking results of step 4 
Comparing parameters are-  
 Protein-legand interaction energy 
 Hydrogen bond energy 
 MolDock score (provided by Molgro virtual docker as its scoring function) 
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Results 
Comparison of parameters of docking result has been shown in Table 1 and Table 2. 
Table 1 Results of comparative parameters of docking of levodopa with corresponding and trans-
disciplinary protein 
 
 
 
 
 
 
Legand with 
corresponding 
protein 
Pose Protein-legand 
interaction energy 
Hydrogen bond 
energy 
MolDock score 
1 -100.193 
 
-20.1122 
 
-93.4740 
2 -101.056 
 
-22.0621 
 
-89.1538 
3 -102.171 
 
-18.5133 
 
-88.5731 
4 -95.7854 
 
-15.1872 
 
-88.8022 
5 -95.8473 
 
-17.7596 
 
-87.0943 
     
 
 
 
 
Legand with 
trans-
disciplinary 
protein 
1 -103.437 
 
-19.2082 
 
-94.7161 
2 -89.2665 
 
-18.9527 
 
-82.7658 
3 -91.0131 
 
-17.4927 
 
-83.1425 
4 -86.6507 
 
-13.2055 
 
-77.5133 
5 -87.0945 
 
-17.473 
 
-79.3102 
 
Levodopa docked with corresponding protein Levodopa docked with trans-disciplinary 
protein 
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Table 2  Results of comparative parameters of docking of acyclovir with corresponding and trans-
disciplinary protein 
 
 
 
 
 
 
Legand with 
corresponding 
protein 
Pose Protein-legand interaction 
energy 
Hydrogen bond 
energy 
MolDock score 
1 -100.026 
 
-13.3005 
 
-97.1499 
2 -104.416 
 
-10.6236 
 
-96.8315 
3 -92.5594 
 
-7.79648 
 
-96.8769 
4 -87.5527 
 
-7.51684 
 
-85.9688 
5 -91.9402 
 
-9.09093 
 
-86.3360 
     
 
 
 
 
Legand with 
trans-
disciplinary 
protein 
1 -104.315 
 
-10.6867 
 
-102.6410 
2 -106.293 
 
-11.6564 
 
-99.7742 
3 -102.057 
 
-8.96364 
 
-100.8510 
4 -102.62 
 
-15.9242 
 
-101.3580 
5 -101.294 
 
-17.3413 
 
-97.8042 
 
 
Acyclovir docked with corresponding protein Acyclovir docked with trans-disciplinary 
protein 
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Discussion 
Results reveals that the protein-ligand interaction energy, hydrogen bond energy and  MolDock 
scores provided by molegro virtual docker between legands (Levodopa/Acyclovir) and trans-
disciplinary proteins (Deoxycytidine kinase/Human Phenylalanine Hydroxylase) have been 
equivalent or even better than between legands and corresponding proteins (Human Phenylalanine 
Hydroxylase/ Deoxycytidine kinase) respectively.  
Conclusion 
Structural based drug designing is significantly based on the protein-ligand interaction. In this work 
docking procedures are used to predict the binding affinity of legand with the proteins that are not 
recognized for the stated legand, which reveals that this concept would be used to find out the 
alternatives of drugs or it may be used to retrieve the information regarding the undesirable effects 
of a drug as it clearly shows the other possibilities of binding of drug because inside the body for a 
single legand all the receptor sites are available. The beneficial use of this concept may be made on 
further developments. 
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